(Ovarian Cancer) Efficacy of Niraparib Plus Bevacizumab?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Niraparib Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
- October 8, 2019
- Reading time: 2 minutes
On August 29, 2019, Mansoor Raza Mirza published in the medical journal The Lancet a comparative efficacy study: "PARP inhibitor niraparib plus VEGF antibody bevacizumab in platinum-sensitive recurrent ovarian cancer — NSGO-AVANOVA2/ENGOT-ov24 Phase 1/2 trial results."
Trial Design
This Phase 1/2 trial enrolled 97 patients with platinum-sensitive recurrent ovarian cancer in a randomized controlled design:
- Niraparib + bevacizumab group: N=48
- Niraparib monotherapy group: N=49
Primary endpoint: progression-free survival (PFS). Secondary endpoint: disease control rate.
Efficacy Results
At a median follow-up of 16.9 months:
- Median PFS: Niraparib + bevacizumab: 11.9 months / Niraparib alone: 5.5 months
- The niraparib + bevacizumab group showed a 65% reduction in disease progression risk, with a hazard ratio of 0.35 — a statistically significant improvement.
Safety Profile
Grade 3 or higher adverse event rates:
- Niraparib + bevacizumab: 65% (N=31) / Niraparib alone: 45% (N=22)
Most common Grade 3 adverse events:
- Anemia: Niraparib + bevacizumab 15% / Niraparib alone 18%
- Thrombocytopenia: Niraparib + bevacizumab 10% / Niraparib alone 12%
- Hypertension: Niraparib + bevacizumab 21% / Niraparib alone 0%
No patients in either group died due to adverse events.
Conclusions
Based on the NSGO-AVANOVA2/ENGOT-ov24 results, Mansoor Raza Mirza concluded that PARP inhibitor niraparib plus VEGF antibody bevacizumab demonstrated significant improvement in progression-free survival in patients with platinum-sensitive recurrent ovarian cancer across various chemotherapy regimens.
Source: Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 Aug 29.
Tags: #OvarianCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4